-
Mashup Score: 0
The FDA deemed AstraZeneca’s PT027 to have a favorable risk-benefit profile for treating asthma in patients aged 18 or older but was less keen on supporting the drug in younger populations.
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 0
San Diego-based Arcturus Therapeutics signed a strategic collaboration and licensing deal with CSL Seqirus to help develop and commercialize vaccines.
Source: BioSpaceCategories: Infectious Disease, Latest HeadlinesTweet-
“The two companies will work to advance vaccines against COVID-19, influenza, pandemic preparedness and three other common respiratory infectious diseases.” https://t.co/jvmz1X9KDx
-
-
Mashup Score: 0GSK’s Blenrep for Multiple Myeloma Misses Mark in Phase III Confirmatory Trial | BioSpace - 2 year(s) ago
GSKs Blenrep misses the mark in the Phase III DREAMM-3 trial for relapsed or refractory multiple myeloma (RRMM), possibly putting the drug’s continued approval at risk.
Source: BioSpaceCategories: Hem/Oncs, Latest HeadlinesTweet-
DREAMM-3: Phase III, randomised head-to-head superiority trial of Blenrep vs PomDex in RRMM did not meet its primary endpoint of PFS) #mmsm https://t.co/QL0fgunmFY #jobs
-
-
Mashup Score: 4Roche introduces the navify brand for its digital health solutions at HLTH 2022 | BioSpace - 2 year(s) ago
Roche introduces the navify brand for its digital health solutions at HLTH 2022 – read this article along with other careers information, tips and advice on BioSpace
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
Roche just introduced the "navify" brand for its digital health solutions. When Roche acquired the diabetes startup MySugr, it became clear that they bet on #digitalhealth. Now it's a huge step for them and other pharma companies into a new realm. https://t.co/AKk6GzlK2M https://t.co/KwkQEGHpe6
-
-
Mashup Score: 1Roche introduces the navify brand for its digital health solutions at HLTH 2022 | BioSpace - 2 year(s) ago
Roche introduces the navify brand for its digital health solutions at HLTH 2022 – read this article along with other careers information, tips and advice on BioSpace
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
Roche just introduced the "navify" brand for its digital health solutions. When Roche acquired the diabetes startup MySugr, it became clear that they bet on #digitalhealth. Now it's a huge step for them and other pharma companies into a new realm. https://t.co/AKk6GzlK2M
-
-
Mashup Score: 2
An investigator in the Phase III trial for Biogen and Eisai’s experimental Alzhiemer’s drug, lecanemab, is attributing a patient’s death to the treatment.
Source: BioSpaceCategories: Hem/Oncs, Latest HeadlinesTweet-
@barttels2 @MadhavThambiset @AlbertoEspay @AE_MD @LonSchneiderMD @ProfRobHoward @jasonkarlawish @MemoryDoc @geoperry @samgandy @cureffi @adamfeuerstein @damiangarde @PLutsey @Jasonmmast @EisaiUS @maxonwifi Eisai Responds to Claims Linking Patient Death to Lecanemab https://t.co/Jdh98VKHES via @H_M_MAC
-
-
Mashup Score: 0Gilead's Hopes for HDV Approval Delayed after CRL | BioSpace - 2 year(s) ago
The FDA issued a Complete Response Letter regarding Gilead’s Biologics License Application for bulevirtide, citing concerns regarding the manufacture and delivery of the drug.
Source: BioSpaceCategories: Infectious Disease, Latest HeadlinesTweet-
“The drug was previously granted conditional approval in Europe for the treatment of HDV, the most severe form of viral hepatitis, where it is marketed under the brand name Helcludex.” https://t.co/1mdYweViru
-
-
Mashup Score: 0
An FDA adcomm that met Wednesday to vote on GlaxoSmithKline’s daprodustat for adult patients with anemia due to chronic kidney disease (CKD) produced mixed results.
Source: BioSpaceCategories: Cardiologists, Latest HeadlinesTweet-
FDA Adcomm Returns Mixed Vote on GSK’s CKD Drug https://t.co/U0y4QRzU5B
-
-
Mashup Score: 1
Biogen and others are seeing the value in, particularly, non-prescription digital therapeutics, as complementary companion therapies to disease-modifying drugs.
Source: BioSpaceCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @chriswasden: good review of opportunities for #dtx in #pharma https://t.co/O1vFkGDQ9j
-
-
Mashup Score: 0Early Human Data Validates Effectiveness of Pfizer-BioNTech Omicron Booster | BioSpace - 2 year(s) ago
Pfizer and BioNTech released early data Thursday morning from a Phase II/III trial assessing an Omicron-specific booster that showed it provided significant protection, confirming early research.
Source: BioSpaceCategories: Infectious Disease, Latest HeadlinesTweet-
Would like to see comparative data from original booster as well as clinical data on efficacy vs. infection. What is the absolute risk reduction with this updated vaccine vs. original vaccine? https://t.co/tuIx5o5cSF
-
FDA Adcomm Backs AstraZeneca's Asthma Drug for Adults, but not Children | BioSpace https://t.co/JXUknr9Jnk